evidence/gaps
Cochrane · systematic review · CD009528

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis

Smith, S, Waters, V, Jahnke, N, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Cystic Fibrosis and Genetic Disorders2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 2 · 33.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Summary of findings

Population: adults and children with cystic fibrosis and P aeruginosa
6 questions
OutcomeEffectEvidenceStatus / GRADE
FEV1 change from start of treatment (L)
no estimate extracted2 studies · 68 participantsHigh
FEV1 change from start of treatment (% predicted)
no estimate extracted1 study · 34 participantsModerate
Downgraded: imprecision
Time to next exacerbation
no estimate extracted1 study · 39 participantsModerate
Downgraded: imprecision
Adverse events: number of moderate adverse events
RR 0.36 [0.07, 1.77]2 studies · 73 participantsModerate
Downgraded: imprecision
Sputum density: change in P aeruginosa sputum density (log1₀ CFU/g)
no estimate extracted2 studies · 70 participantsHigh
Quality of life: change in CFQ‐R score from start of treatment
no estimate extracted1 study · 38 participantsModerate
Downgraded: imprecision